Neurescue

Neurescue has developed a pioneering medical device to an improve the treatment of cardiac arrest, the leading cause of death in the world.

Location
Copenhagen, Denmark
Revenue size
0 (pre-revenue)
Year founded
2014
Funding raised
EUR 11 Million
Founder
Habib Frost
Most relevant investors
TAG Holding, GreenOcean Capital, Nina Capital, Nordic Impact
Team size
No. of employees 1-9
Website

www.neurescue.com

Problem

Cardiac arrest is the leading cause of death globally, causing up to 9 million fatalities annually. Today, the treatment consists of chest compressions and defibrillation, and only 10% survive with the current treatment

SOLUTION

Neurescue seeks to improve the current low survival rate with their breakthrough device; the world’s first computer-aided aortic occlusion catheter with pressure-controlled inflation and position feedback.

The balloon is advanced into the aorta through the femoral artery and temporarily inflated, thereby redirecting blood flow to the heart and the brain. The increased blood flow may increase the chance of immediate resuscitation from chest compressions and defibrillation, but may also increase the treatment time window, allowing the patient more time to receive advanced treatments.

Asia Connection

Neurescue is looking to connect with strategic partners and distribution partners, preferably with experience with global medical device distribution, including the Japanese PMDA process and reimbursement system, and knowledge of the trauma and cardiac arrest market.

Neurescue is also interested in exploring a strategic partnership for funding or acquisition from the East Asian region.

Pitch

GET IN TOUCH WITH

Neurescue